Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

A method for semi-automated image analysis of HLA class I tumour epithelium expression in rectal cancer.

Krijgsman D, Van Vlierberghe RLP, Evangelou V, Vahrmeijer AL, Van de Velde CJH, Sier CFM, Kuppen PJK.

Eur J Histochem. 2019 May 20;63(2). doi: 10.4081/ejh.2019.3028.

2.

Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.

Krijgsman D, de Vries NL, Skovbo A, Andersen MN, Swets M, Bastiaannet E, Vahrmeijer AL, van de Velde CJH, Heemskerk MHM, Hokland M, Kuppen PJK.

Cancer Immunol Immunother. 2019 Jun;68(6):1011-1024. doi: 10.1007/s00262-019-02343-7. Epub 2019 May 3.

3.

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.

de Groot AF, Blok EJ, Charehbili A, Engels CC, Smit VTHBM, Dekker-Ensink NG, Putter H, Meershoek-Klein Kranenbarg E, van de Velde CJH, Liefers GJ, Nortier JWR, Kuppen PJK, van der Burg SH, Kroep JR.

Breast Cancer Res Treat. 2019 Jun;175(3):605-615. doi: 10.1007/s10549-019-05195-y. Epub 2019 Mar 13.

4.

Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation.

Boogerd LSF, Boonstra MC, Prevoo HAJM, Handgraaf HJM, Kuppen PJK, van de Velde CJH, Fish A, Cordfunke RA, Valentijn ARPM, Terwisscha van Scheltinga AG, MacDonald GC, Cizeau J, Premsukh A, Vinkenburg van Slooten ML, Burggraaf J, Sier CFM, Vahrmeijer AL.

Surg Oncol. 2019 Mar;28:1-8. doi: 10.1016/j.suronc.2018.10.004. Epub 2018 Oct 23.

PMID:
30851880
5.

Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.

Sandberg TP, Sweere I, van Pelt GW, Putter H, Vermeulen L, Kuppen PJ, Tollenaar RAEM, Mesker WE.

Cell Oncol (Dordr). 2019 Jun;42(3):397-403. doi: 10.1007/s13402-019-00436-0. Epub 2019 Mar 8.

PMID:
30847807
6.

Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.

Trinh A, Lädrach C, Dawson HE, Ten Hoorn S, Kuppen PJK, Reimers MS, Koopman M, Punt CJA, Lugli A, Vermeulen L, Zlobec I.

Br J Cancer. 2018 Nov;119(10):1244-1251. doi: 10.1038/s41416-018-0230-7. Epub 2018 Nov 2.

PMID:
30385823
7.

Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.

Nazemalhosseini-Mojarad E, Mohammadpour S, Torshizi Esafahani A, Gharib E, Larki P, Moradi A, Amin Porhoseingholi M, Asadzade Aghdaei H, Kuppen PJK, Zali MR.

J Cell Physiol. 2019 Apr;234(4):4768-4777. doi: 10.1002/jcp.27273. Epub 2018 Oct 28.

PMID:
30370522
8.

HLA-G protein expression in colorectal cancer evaluated by immunohistochemistry and western blot analysis: Its expression characteristics remain enigmatic.

Swets M, Wouters A, Krijgsman D, van Vlierberghe RLP, Boot A, van Eendenburg JD, van Wezel T, Gelderblom H, van de Velde CJH, van den Elsen PJ, Kuppen PJK.

Clin Immunol. 2018 Sep;194:80-86. doi: 10.1016/j.clim.2018.07.005. Epub 2018 Jul 10.

PMID:
30006120
9.

The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.

Vangangelt KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, Dekker TJA, Kuppen PJK, Tollenaar RAEM, Mesker WE.

Int J Cancer. 2018 Dec 15;143(12):3194-3200. doi: 10.1002/ijc.31658. Epub 2018 Oct 16.

PMID:
29978463
10.

Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.

Blok EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, Putter H, Smit VTHBM, Liefers GJ, Morden JP, Bliss JM, Coombes RC, Bartlett JMS, Kroep JR, van de Velde CJH, Kuppen PJK.

Breast Cancer Res Treat. 2018 Aug;171(1):65-74. doi: 10.1007/s10549-018-4785-z. Epub 2018 May 15.

PMID:
29766362
11.

The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.

Krijgsman D, Hokland M, Kuppen PJK.

Front Immunol. 2018 Feb 27;9:367. doi: 10.3389/fimmu.2018.00367. eCollection 2018. Review.

12.

Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma.

Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit VTHBM, Tollenaar RAEM, Kuppen PJK, Mesker WE.

Breast Cancer Res Treat. 2018 Apr;168(3):601-612. doi: 10.1007/s10549-017-4617-6. Epub 2017 Dec 22.

13.

Genes associated with venous thromboembolism in colorectal cancer patients.

Ünlü B, van Es N, Arindrarto W, Kiełbasa SM, Mei H, Westerga J, Middeldorp S, Kuppen PJK, Otten JMMB, Cannegieter S, Versteeg HH.

J Thromb Haemost. 2018 Feb;16(2):293-302. doi: 10.1111/jth.13926. Epub 2018 Jan 15.

PMID:
29247594
14.

Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?

Swets M, Kuppen PJK, Blok EJ, Gelderblom H, van de Velde CJH, Nagtegaal ID.

Eur J Cancer. 2018 Jan;89:1-8. doi: 10.1016/j.ejca.2017.11.006. Epub 2017 Dec 7.

PMID:
29223019
15.

Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.

Roelands J, Kuppen PJK, Vermeulen L, Maccalli C, Decock J, Wang E, Marincola FM, Bedognetti D, Hendrickx W.

Int J Mol Sci. 2017 Oct 24;18(10). pii: E2229. doi: 10.3390/ijms18102229. Review.

16.

Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines.

Boot A, Oosting J, van Eendenburg JDH, Kuppen PJK, Morreau H, van Wezel T.

PLoS One. 2017 Sep 20;12(9):e0184900. doi: 10.1371/journal.pone.0184900. eCollection 2017.

17.

Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma.

Tummers WS, Farina-Sarasqueta A, Boonstra MC, Prevoo HA, Sier CF, Mieog JS, Morreau J, van Eijck CH, Kuppen PJ, van de Velde CJ, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ.

Oncotarget. 2017 May 26;8(34):56816-56828. doi: 10.18632/oncotarget.18232. eCollection 2017 Aug 22.

18.

Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.

de Geus SW, Baart VM, Boonstra MC, Kuppen PJ, Prevoo HA, Mazar AP, Bonsing BA, Morreau H, van de Velde CJ, Vahrmeijer AL, Sier CF.

Biomark Insights. 2017 Jun 22;12:1177271917715443. doi: 10.1177/1177271917715443. eCollection 2017. Review.

19.

Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue.

Boogerd LSF, Vuijk FA, Hoogstins CES, Handgraaf HJM, van der Valk MJM, Kuppen PJK, Sier CFM, van de Velde CJH, Burggraaf J, Fariña-Sarasqueta A, Vahrmeijer AL.

Biomark Cancer. 2017 May 17;9:1179299X17710016. doi: 10.1177/1179299X17710016. eCollection 2017.

20.

Statin Use After Diagnosis of Colon Cancer and Patient Survival.

Voorneveld PW, Reimers MS, Bastiaannet E, Jacobs RJ, van Eijk R, Zanders MMJ, Herings RMC, van Herk-Sukel MPP, Kodach LL, van Wezel T, Kuppen PJK, Morreau H, van de Velde CJH, Hardwick JCH, Liefers GJ.

Gastroenterology. 2017 Aug;153(2):470-479.e4. doi: 10.1053/j.gastro.2017.05.011. Epub 2017 May 13.

PMID:
28512021
21.

Morphological and phenotypical features of ovarian metastases in breast cancer patients.

Peters IT, van der Steen MA, Huisman BW, Hilders CG, Smit VT, Vahrmeijer AL, Sier CF, Trimbos JB, Kuppen PJ.

BMC Cancer. 2017 Mar 21;17(1):206. doi: 10.1186/s12885-017-3191-y.

22.

Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.

Stammes MA, Prevoo HA, Ter Horst MC, Groot SA, Van de Velde CJ, Chan AB, de Geus-Oei LF, Kuppen PJ, Vahrmeijer AL, Pasquale EB, Sier CF.

Int J Mol Sci. 2017 Feb 3;18(2). pii: E307. doi: 10.3390/ijms18020307.

23.

The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis.

Frouws MA, Reimers MS, Swets M, Bastiaannet E, Prinse B, van Eijk R, Lemmens VE, van Herk-Sukel MP, van Wezel T, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ.

PLoS One. 2017 Jan 26;12(1):e0170775. doi: 10.1371/journal.pone.0170775. eCollection 2017.

24.

Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.

Peters IT, van Zwet EW, Smit VT, Liefers GJ, Kuppen PJ, Hilders CG, Trimbos JB.

PLoS One. 2017 Jan 26;12(1):e0168277. doi: 10.1371/journal.pone.0168277. eCollection 2017.

25.

Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.

Blok EJ, van den Bulk J, Dekker-Ensink NG, Derr R, Kanters C, Bastiaannet E, Kroep JR, van de Velde CJ, Kuppen PJ.

Oncotarget. 2017 Feb 28;8(9):15610-15620. doi: 10.18632/oncotarget.14779.

26.

Tumor LINE-1 Methylation Level in Association with Survival of Patients with Stage II Colon Cancer.

Swets M, Zaalberg A, Boot A, van Wezel T, Frouws MA, Bastiaannet E, Gelderblom H, van de Velde CJ, Kuppen PJ.

Int J Mol Sci. 2016 Dec 27;18(1). pii: E36. doi: 10.3390/ijms18010036.

27.

EpCAM as multi-tumour target for near-infrared fluorescence guided surgery.

van Driel PB, Boonstra MC, Prevoo HA, van de Giessen M, Snoeks TJ, Tummers QR, Keereweer S, Cordfunke RA, Fish A, van Eendenburg JD, Lelieveldt BP, Dijkstra J, van de Velde CJ, Kuppen PJ, Vahrmeijer AL, Löwik CW, Sier CF.

BMC Cancer. 2016 Nov 14;16(1):884.

28.

Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.

de Geus SW, Boogerd LS, Swijnenburg RJ, Mieog JS, Tummers WS, Prevoo HA, Sier CF, Morreau H, Bonsing BA, van de Velde CJ, Vahrmeijer AL, Kuppen PJ.

Mol Imaging Biol. 2016 Dec;18(6):807-819.

29.

Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Boonstra MC, de Geus SW, Prevoo HA, Hawinkels LJ, van de Velde CJ, Kuppen PJ, Vahrmeijer AL, Sier CF.

Biomark Cancer. 2016 Sep 27;8:119-133. eCollection 2016. Review.

30.

Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation.

Hoekstra E, Das AM, Willemsen M, Swets M, Kuppen PJ, van der Woude CJ, Bruno MJ, Shah JP, Ten Hagen TL, Chisholm JD, Kerr WG, Peppelenbosch MP, Fuhler GM.

Oncotarget. 2016 Nov 8;7(45):73525-73540. doi: 10.18632/oncotarget.12321.

31.

Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.

Trinh A, Trumpi K, De Sousa E Melo F, Wang X, de Jong JH, Fessler E, Kuppen PJ, Reimers MS, Swets M, Koopman M, Nagtegaal ID, Jansen M, Hooijer GK, Offerhaus GJ, Kranenburg O, Punt CJ, Medema JP, Markowetz F, Vermeulen L.

Clin Cancer Res. 2017 Jan 15;23(2):387-398. doi: 10.1158/1078-0432.CCR-16-0680. Epub 2016 Jul 26.

32.

Low Level of Microsatellite Instability Correlates with Poor Clinical Prognosis in Stage II Colorectal Cancer Patients.

Nazemalhosseini Mojarad E, Kashfi SM, Mirtalebi H, Taleghani MY, Azimzadeh P, Savabkar S, Pourhoseingholi MA, Jalaeikhoo H, Asadzadeh Aghdaei H, Kuppen PJ, Zali MR.

J Oncol. 2016;2016:2196703. doi: 10.1155/2016/2196703. Epub 2016 Jun 27.

33.

High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue.

Ly A, Buck A, Balluff B, Sun N, Gorzolka K, Feuchtinger A, Janssen KP, Kuppen PJ, van de Velde CJ, Weirich G, Erlmeier F, Langer R, Aubele M, Zitzelsberger H, McDonnell L, Aichler M, Walch A.

Nat Protoc. 2016 Aug;11(8):1428-43. doi: 10.1038/nprot.2016.081. Epub 2016 Jul 14.

PMID:
27414759
34.

The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment.

de Vries NL, Swets M, Vahrmeijer AL, Hokland M, Kuppen PJ.

Int J Mol Sci. 2016 Jun 29;17(7). pii: E1030. doi: 10.3390/ijms17071030. Review.

35.

Promoter methylation and mRNA expression of HLA-G in relation to HLA-G protein expression in colorectal cancer.

Swets M, Seneby L, Boot A, van Wezel T, Gelderblom H, van de Velde CJ, van den Elsen PJ, Kuppen PJ.

Hum Immunol. 2016 Sep;77(9):764-72. doi: 10.1016/j.humimm.2016.05.023. Epub 2016 May 28.

PMID:
27245757
36.

Noninvasive Detection of Metastases and Follicle Density in Ovarian Tissue Using Full-Field Optical Coherence Tomography.

Peters IT, Stegehuis PL, Peek R, Boer FL, van Zwet EW, Eggermont J, Westphal JR, Kuppen PJ, Trimbos JB, Hilders CG, Lelieveldt BP, van de Velde CJ, Bosse T, Dijkstra J, Vahrmeijer AL.

Clin Cancer Res. 2016 Nov 15;22(22):5506-5513. doi: 10.1158/1078-0432.CCR-16-0288. Epub 2016 May 16.

37.

HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases.

Swets M, König MH, Zaalberg A, Dekker-Ensink NG, Gelderblom H, van de Velde CJ, van den Elsen PJ, Kuppen PJ.

Hum Immunol. 2016 Sep;77(9):773-9. doi: 10.1016/j.humimm.2016.03.001. Epub 2016 Mar 8.

PMID:
26968946
38.

The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.

Engels CC, Kiderlen M, Bastiaannet E, van Eijk R, Mooyaart A, Smit VT, de Craen AJ, Kuppen PJ, Kroep JR, van de Velde CJ, Liefers GJ.

Breast Cancer Res Treat. 2016 Apr;156(2):361-70. doi: 10.1007/s10549-016-3734-y. Epub 2016 Mar 11.

39.

Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue.

Peters IT, Hilders CG, Sier CF, Vahrmeijer AL, Smit VT, Baptist Trimbos J, Kuppen PJ.

Arch Gynecol Obstet. 2016 Aug;294(2):385-93. doi: 10.1007/s00404-016-4036-7. Epub 2016 Mar 5.

40.

Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome.

Hoekstra E, Das AM, Swets M, Cao W, van der Woude CJ, Bruno MJ, Peppelenbosch MP, Kuppen PJ, Ten Hagen TL, Fuhler GM.

Oncotarget. 2016 Apr 19;7(16):21922-38. doi: 10.18632/oncotarget.7829.

41.

The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A FOCUS study analysis.

Engels CC, Kiderlen M, Bastiaannet E, Mooyaart AL, van Vlierberghe R, Smit VT, Kuppen PJ, van de Velde CJ, Liefers GJ.

Mol Oncol. 2016 Apr;10(4):594-600. doi: 10.1016/j.molonc.2015.11.002. Epub 2015 Nov 24.

42.

The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.

Engels CC, de Glas NA, Sajet A, Bastiaannet E, Smit VT, Kuppen PJ, Seynaeve C, van de Velde CJ, Liefers GJ.

Mol Oncol. 2016 Apr;10(4):509-16. doi: 10.1016/j.molonc.2015.10.010. Epub 2015 Oct 31.

43.

Stromal Targets for Fluorescent-Guided Oncologic Surgery.

Boonstra MC, Prakash J, Van De Velde CJ, Mesker WE, Kuppen PJ, Vahrmeijer AL, Sier CF.

Front Oncol. 2015 Nov 20;5:254. doi: 10.3389/fonc.2015.00254. eCollection 2015. Review.

44.

Novel avenues in immunotherapies for colorectal cancer.

Pardieck IN, Jawahier PA, Swets M, van de Velde CJ, Kuppen PJ.

Expert Rev Gastroenterol Hepatol. 2016;10(4):465-80. doi: 10.1586/17474124.2016.1122522. Epub 2015 Dec 17. Review.

PMID:
26582071
45.

Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression.

Kocatürk B, Tieken C, Vreeken D, Ünlü B, Engels CC, de Kruijf EM, Kuppen PJ, Reitsma PH, Bogdanov VY, Versteeg HH.

J Thromb Haemost. 2015 Sep;13(9):1683-93. doi: 10.1111/jth.13049. Epub 2015 Jul 31.

46.

Copy number alterations and allelic ratio in relation to recurrence of rectal cancer.

Goossens-Beumer IJ, Oosting J, Corver WE, Janssen MJ, Janssen B, van Workum W, Zeestraten EC, van de Velde CJ, Morreau H, Kuppen PJ, van Wezel T.

BMC Genomics. 2015 Jun 6;16:438. doi: 10.1186/s12864-015-1550-0.

47.

High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed, paraffin-embedded clinical tissue samples.

Buck A, Ly A, Balluff B, Sun N, Gorzolka K, Feuchtinger A, Janssen KP, Kuppen PJ, van de Velde CJ, Weirich G, Erlmeier F, Langer R, Aubele M, Zitzelsberger H, Aichler M, Walch A.

J Pathol. 2015 Sep;237(1):123-32. doi: 10.1002/path.4560. Epub 2015 Jun 30.

PMID:
25965788
48.

Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors.

Boonstra MC, Tolner B, Schaafsma BE, Boogerd LS, Prevoo HA, Bhavsar G, Kuppen PJ, Sier CF, Bonsing BA, Frangioni JV, van de Velde CJ, Chester KA, Vahrmeijer AL.

Int J Cancer. 2015 Oct 15;137(8):1910-20. doi: 10.1002/ijc.29571. Epub 2015 Jun 22.

49.

uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.

Boonstra MC, van Driel PB, van Willigen DM, Stammes MA, Prevoo HA, Tummers QR, Mazar AP, Beekman FJ, Kuppen PJ, van de Velde CJ, Löwik CW, Frangioni JV, van Leeuwen FW, Sier CF, Vahrmeijer AL.

Oncotarget. 2015 Jun 10;6(16):14260-73.

50.

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.

Engels CC, Charehbili A, van de Velde CJ, Bastiaannet E, Sajet A, Putter H, van Vliet EA, van Vlierberghe RL, Smit VT, Bartlett JM, Seynaeve C, Liefers GJ, Kuppen PJ.

Breast Cancer Res Treat. 2015 Feb;149(3):587-96. doi: 10.1007/s10549-015-3269-7. Epub 2015 Jan 24.

Supplemental Content

Loading ...
Support Center